<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10086436
   </pmid>
   <datecreated>
    <year>
     1999
    </year>
    <month>
     03
    </month>
    <day>
     24
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1999
    </year>
    <month>
     03
    </month>
    <day>
     24
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     19
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0098-7484
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       281
      </volume>
      <issue>
       11
      </issue>
      <pubdate>
       <year>
        1999
       </year>
       <month>
        Mar
       </month>
       <day>
        17
       </day>
      </pubdate>
     </journalissue>
     <title>
      JAMA : the journal of the American Medical Association
     </title>
     <isoabbreviation>
      JAMA
     </isoabbreviation>
    </journal>
    <articletitle>
     Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.
    </articletitle>
    <pagination>
     <medlinepgn>
      1014-8
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="CONTEXT" nlmcategory="BACKGROUND">
      Isoniazid preventive therapy for latent tuberculosis (TB) infection has been debated because of the risk of hepatotoxicity. The frequency of hepatotoxicity was 0.5% to 2.0% in early studies but may have changed with new criteria for diagnosis and patient selection.
     </abstracttext>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To determine the rate of isoniazid hepatotoxicity in patients managed according to current guidelines and practice standards.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Prospective cohort study.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      A public health clinic operated by the TB control program of a city-county public health agency.
     </abstracttext>
     <abstracttext label="PATIENTS" nlmcategory="METHODS">
      A total of 11141 consecutive patients who started a regimen of isoniazid preventive therapy for latent TB infection from January 1989 through December 1995.
     </abstracttext>
     <abstracttext label="MAIN OUTCOME MEASURES" nlmcategory="METHODS">
      The rate of developing symptoms and signs of hepatotoxicity among all persons starting isoniazid preventive therapy, among all those completing therapy, and by age, sex, and race.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Eleven patients (0.10% of those starting, and 0.15% of those completing treatment) had hepatotoxic reactions to isoniazid during preventive treatment. The rate of hepatotoxicity in persons receiving preventive therapy increased with increasing age (chi2 for linear trend = 5.22, P=.02) and there were trends toward increased rates in women (odds ratio [OR], 3.30; 95% confidence interval [CI], 0.87-12.45; chi2 = 3.28; P=.07) and in whites (OR, 2.60; 95% CI, 0.75-8.95; chi2 = 3.08; P=.08).
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      The rate of isoniazid hepatotoxicity during clinically monitored preventive therapy was lower than has been reported previously. Clinicians should have greater confidence in the safety of isoniazid preventive therapy.
     </abstracttext>
    </abstract>
    <affiliation>
     Seattle-King County Department of Public Health, Department of Medicine, University of Washington, 98104, USA. charles.nolan@metrokc.gov
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Nolan
      </lastname>
      <forename>
       C M
      </forename>
      <initials>
       CM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Goldberg
      </lastname>
      <forename>
       S V
      </forename>
      <initials>
       SV
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Buskin
      </lastname>
      <forename>
       S E
      </forename>
      <initials>
       SE
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     JAMA
    </medlineta>
    <nlmuniqueid>
     7501160
    </nlmuniqueid>
    <issnlinking>
     0098-7484
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antitubercular Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      54-85-3
     </registrynumber>
     <nameofsubstance>
      Isoniazid
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      JAMA. 1999 Dec 15;282(23):2207-8
     </refsource>
     <pmid version="1">
      10605965
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antitubercular Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug-Induced Liver Injury
     </descriptorname>
     <qualifiername majortopicyn="N">
      epidemiology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Isoniazid
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Logistic Models
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prospective Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tuberculosis
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1999
     </year>
     <month>
      3
     </month>
     <day>
      23
     </day>
     <hour>
      3
     </hour>
     <minute>
      3
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2000
     </year>
     <month>
      3
     </month>
     <day>
      4
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1999
     </year>
     <month>
      3
     </month>
     <day>
      23
     </day>
     <hour>
      3
     </hour>
     <minute>
      3
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10086436
    </articleid>
    <articleid idtype="pii">
     joc80897
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

